Treatment and survival of patients with pancreatic ductal adenocarcinoma: 15-year national cohort.

ABSTRACT:

Background

Improvement in survival from pancreatic ductal adenocarcinoma (PDAC) has been reported in trial settings but is less explored in unselected cohorts. The aim of this study was to assess trends in provision of treatments and survival in Norway over a 15-year period following the implementation of hepato-pancreato-biliary (HPB) multidisciplinary teams, centralization of surgery, and implementation of modern chemotherapy (CTx) regimens.

Methods

A population-based observational study was conducted by analysing all patients diagnosed with PDAC between 2004 and 2018 using coupled data from the Cancer Registry of Norway and the National Patient Registry.

Results

A total of 10 630 patients were identified, of whom 1492 (14.0 per cent) underwent surgical resection. T

SUBMITTER: Nymo LS 

PROVIDER: S-EPMC8902330 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature